SEC Form 4 · accession 0001179110-19-000231
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Alpern
Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Equivalent UnitsF2,F1 | $0.00 | Dec 31, 2018 | A | 74 | A | — | — | Common Stock | 74 | 6,222 | D |
Explanation of responses
- F1Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- F2Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.